Author | Feliza Mirasol

MMHGroup

Articles

Bio/Pharma Industry Works Overtime to Find COVID-19 Therapies

Article

Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.

GMPs Guide COVID-19 Vaccine Manufacturing

Article

Recent industry guidance aims to anchor rapid COVID-19 vaccine development in good manufacturing practice protocols.

Navigating Cell Therapy Manufacturing Amid Pandemic Woes

Article

Automation, digitalization, and supply-chain strategies help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.

Synthetic Biology Offers a Solution to Cell Therapy Source Material Constraints

Article

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.